Published Guideline
READ GUIDELINE
Updated Content
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines, SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “SITC Living Guidelines” rapid update protocols designed to ensure SITC CPGs are up-to-date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital service to treating clinicians and those along the whole cancer care continuum.
The information below provides an overview of the updates made to the "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma" since its publication in Journal for ImmunoTherapy of Cancer (JITC).
Rapid Update v1.4 Summary
An update to the SITC Lymphoma CPG is currently in preparation to address practice-changing data and new FDA approvals of immune checkpoint inhibitors, CAR T cell therapy, antibody-drug conjugates, monoclonal antibodies, bispecific T cell engagers, immunomodulatory agents, and a cytotoxic recombinant protein. These approvals and practice-changing data will affect the recommendations across a variety of disease states within this guideline.
Rapid Update v1.3 Summary
- Based on the approval of axicabtagene ciloleucel for adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy, the Lymphoma CPG has been updated in the "Available Agents and Indications for NHL" and "Expert Panel Recommendations for NHL" sections.
- Based on the approval of tisagenlecleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy, the Lymphoma CPG has been updated in the "Available Agents and Indications for NHL" section.
- Based on the approval of lisocabtagene maraleucel for the treatment of adult patients with large B-cell lymphoma (LBCL) who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age, the Lymphoma CPG has been updated in the "Available Agents and Indications for NHL" section.
Rapid Update v1.2 Summary
- Based on the approval of loncastuximab tesirine-lpyl for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma, the Lymphoma CPG has been updated in the "Available Agents and Indications for NHL" section.
Rapid Update v1.1 Summary
- Updates to narrative text and recommendations based on approval for axicabtagene ciloleucel for second-line treatment of LBCL.
- Update to narrative text based on approval of loncastuximab tesirine-lpyl.
- Update to narrative text based on approval of lisocabtagene maraleucel.
- Updates to the narrative text based on approval of tisagenlecleucel.